Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes

Kunal C. Kadakia, Charles Lawrence Loprinzi, Pamela J. Atherton, Kelliann C. Fee-Schroeder, Amit Sood, Debra L. Barton

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines. Methods: This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25 %. The women kept a daily hot flash diary during a baseline week and then daily during weeks 2–7. The primary endpoint was the change from baseline to week 7 in hot flash score and hot flash frequency. Secondary endpoints included toxicity analyses and the effect of SAMe on QOL. Results: From October 28, 2010 to January 30, 2012, 43 women were treated with SAMe. The decrease in mean percent of baseline hot flash score and frequency was 35.4 and 32.6 %, respectively. When compared to the historical placebo response of 25 %, the effect of SAMe on hot flash score was not statistically significant (p = 0.09). Treatment was well tolerated with expected grade 1/2 gastrointestinal toxicity and no negative effect on QOL. Conclusions: The use of SAMe does not appear to significantly reduce hot flashes more than would be expected with a placebo.

Original languageEnglish (US)
Pages (from-to)1061-1069
Number of pages9
JournalSupportive Care in Cancer
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hot Flashes
S-Adenosylmethionine
Therapeutics
Placebos
Quality of Life
Complementary Therapies
Antidepressive Agents
Estrogens

Keywords

  • Clinical trials
  • Hot flashes
  • Quality of life
  • S-Adenosyl-L-methionine
  • SAMe

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. / Kadakia, Kunal C.; Loprinzi, Charles Lawrence; Atherton, Pamela J.; Fee-Schroeder, Kelliann C.; Sood, Amit; Barton, Debra L.

In: Supportive Care in Cancer, Vol. 24, No. 3, 01.03.2016, p. 1061-1069.

Research output: Contribution to journalArticle

Kadakia, Kunal C. ; Loprinzi, Charles Lawrence ; Atherton, Pamela J. ; Fee-Schroeder, Kelliann C. ; Sood, Amit ; Barton, Debra L. / Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. In: Supportive Care in Cancer. 2016 ; Vol. 24, No. 3. pp. 1061-1069.
@article{a37b5bda332a45388bfec02c5f1733ef,
title = "Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes",
abstract = "Purpose: Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines. Methods: This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25 {\%}. The women kept a daily hot flash diary during a baseline week and then daily during weeks 2–7. The primary endpoint was the change from baseline to week 7 in hot flash score and hot flash frequency. Secondary endpoints included toxicity analyses and the effect of SAMe on QOL. Results: From October 28, 2010 to January 30, 2012, 43 women were treated with SAMe. The decrease in mean percent of baseline hot flash score and frequency was 35.4 and 32.6 {\%}, respectively. When compared to the historical placebo response of 25 {\%}, the effect of SAMe on hot flash score was not statistically significant (p = 0.09). Treatment was well tolerated with expected grade 1/2 gastrointestinal toxicity and no negative effect on QOL. Conclusions: The use of SAMe does not appear to significantly reduce hot flashes more than would be expected with a placebo.",
keywords = "Clinical trials, Hot flashes, Quality of life, S-Adenosyl-L-methionine, SAMe",
author = "Kadakia, {Kunal C.} and Loprinzi, {Charles Lawrence} and Atherton, {Pamela J.} and Fee-Schroeder, {Kelliann C.} and Amit Sood and Barton, {Debra L.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00520-015-2878-3",
language = "English (US)",
volume = "24",
pages = "1061--1069",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes

AU - Kadakia, Kunal C.

AU - Loprinzi, Charles Lawrence

AU - Atherton, Pamela J.

AU - Fee-Schroeder, Kelliann C.

AU - Sood, Amit

AU - Barton, Debra L.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines. Methods: This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25 %. The women kept a daily hot flash diary during a baseline week and then daily during weeks 2–7. The primary endpoint was the change from baseline to week 7 in hot flash score and hot flash frequency. Secondary endpoints included toxicity analyses and the effect of SAMe on QOL. Results: From October 28, 2010 to January 30, 2012, 43 women were treated with SAMe. The decrease in mean percent of baseline hot flash score and frequency was 35.4 and 32.6 %, respectively. When compared to the historical placebo response of 25 %, the effect of SAMe on hot flash score was not statistically significant (p = 0.09). Treatment was well tolerated with expected grade 1/2 gastrointestinal toxicity and no negative effect on QOL. Conclusions: The use of SAMe does not appear to significantly reduce hot flashes more than would be expected with a placebo.

AB - Purpose: Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines. Methods: This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25 %. The women kept a daily hot flash diary during a baseline week and then daily during weeks 2–7. The primary endpoint was the change from baseline to week 7 in hot flash score and hot flash frequency. Secondary endpoints included toxicity analyses and the effect of SAMe on QOL. Results: From October 28, 2010 to January 30, 2012, 43 women were treated with SAMe. The decrease in mean percent of baseline hot flash score and frequency was 35.4 and 32.6 %, respectively. When compared to the historical placebo response of 25 %, the effect of SAMe on hot flash score was not statistically significant (p = 0.09). Treatment was well tolerated with expected grade 1/2 gastrointestinal toxicity and no negative effect on QOL. Conclusions: The use of SAMe does not appear to significantly reduce hot flashes more than would be expected with a placebo.

KW - Clinical trials

KW - Hot flashes

KW - Quality of life

KW - S-Adenosyl-L-methionine

KW - SAMe

UR - http://www.scopus.com/inward/record.url?scp=84955701011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955701011&partnerID=8YFLogxK

U2 - 10.1007/s00520-015-2878-3

DO - 10.1007/s00520-015-2878-3

M3 - Article

VL - 24

SP - 1061

EP - 1069

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -